Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
135.60M | 136.10M | 113.21M | 91.29M | 79.86M | 82.50M | Gross Profit |
65.40M | 93.60M | 21.01M | 15.34M | 10.02M | 14.35M | EBIT |
27.00M | 21.60M | 21.13M | 15.25M | 9.96M | 14.35M | EBITDA |
39.30M | 35.60M | 29.00M | 20.33M | 15.17M | 18.54M | Net Income Common Stockholders |
14.90M | 9.50M | 12.50M | 12.68M | 8.22M | 11.38M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
15.73M | 13.70M | 20.83M | 18.41M | 15.52M | 14.12M | Total Assets |
65.73M | 183.50M | 185.79M | 88.98M | 82.03M | 70.61M | Total Debt |
15.03M | 65.30M | 59.95M | 21.32M | 26.37M | 18.90M | Net Debt |
-701.00K | 51.60M | 39.12M | 2.91M | 10.85M | 4.77M | Total Liabilities |
34.52M | 100.90M | 131.33M | 45.58M | 48.98M | 41.92M | Stockholders Equity |
30.64M | 82.40M | 54.24M | 42.78M | 32.19M | 27.87M |
Cash Flow | Free Cash Flow | ||||
15.20M | 20.60M | 12.33M | 13.44M | 10.53M | 15.28M | Operating Cash Flow |
21.30M | 26.50M | 20.22M | 16.89M | 11.79M | 16.58M | Investing Cash Flow |
-11.70M | -25.90M | -51.11M | -5.21M | -12.67M | -1.37M | Financing Cash Flow |
-17.40M | -7.60M | 33.21M | -8.81M | 2.34M | -16.76M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | £110.49M | 20.72 | 8.61% | 1.91% | -11.80% | -32.11% | |
76 Outperform | £2.02B | 8.74 | 17.33% | 4.08% | -11.09% | 65.87% | |
74 Outperform | £1.91B | 19.59 | 11.07% | 2.90% | 4.71% | 0.43% | |
71 Outperform | £643.84M | 26.27 | 8.07% | 1.80% | -5.56% | -27.87% | |
70 Outperform | £140.79M | 27.19 | 4.79% | 2.22% | 1.74% | 359.50% | |
70 Neutral | £525.16M | 50.40 | 12.29% | 1.24% | -1.84% | 9.56% | |
62 Neutral | $11.80B | 10.31 | -7.45% | 2.91% | 7.43% | -7.78% |
Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan involving several key executives, including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. Each transaction was conducted on the London Stock Exchange, AIM Market, at a price of 7870.0p per share, reflecting the company’s commitment to aligning management interests with shareholder value.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific announced the acquisition of 28 ordinary shares at a price of 7875p per share, which have been allocated to employees under the company’s reward scheme. This move reflects the company’s ongoing strategy to enhance shareholder value through sustainable profit generation, debt reduction, organic growth, and dividends.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific announced the successful passing of all resolutions at their recent Annual General Meeting, including the approval of financial statements, remuneration reports, and director re-elections. Notably, over 20% of shareholders opposed the re-election of Ralph Elman as a director, prompting the board to engage with shareholders for feedback. This outcome highlights the company’s commitment to stakeholder engagement and governance, potentially impacting its strategic direction and investor relations.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £10600.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific plc announced the acquisition of 655 ordinary shares at a price of 7820p per share, which were immediately allocated to employees as part of the company’s reward scheme. This move reflects the company’s ongoing commitment to rewarding its employees and maintaining a strong operational framework, potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.
Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan involving several key executives, including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. This transaction, conducted on the London Stock Exchange’s AIM Market, reflects the company’s ongoing commitment to aligning the interests of its management team with those of its shareholders, potentially enhancing stakeholder confidence and reinforcing its market position.
Judges Scientific plc has announced the posting of its Annual Report and Accounts along with the Notice of its Annual General Meeting (AGM), scheduled for May 22, 2025, at The Lansdowne Club in London. Shareholders are encouraged to attend the AGM in person or submit proxy votes online. This announcement underscores the company’s commitment to transparency and shareholder engagement, reflecting its strategic focus on sustainable growth and market presence in the scientific instrument sector.
Judges Scientific has announced a significant change in its board and management structure, with Chief Operating Officer Mark Lavelle planning to retire by September 2026. As part of his transition, Lavelle will step down from the board in May 2025 but will continue to contribute to the group through a newly formed Executive Committee, which will oversee the management of the company. This restructuring aims to enhance the group’s operational and growth capabilities, ensuring continued success and development in the scientific instrument sector.
Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan, involving several key executives including the CEO, CFO, COO, and other directors. This move, conducted on the London Stock Exchange’s AIM Market, reflects a strategic effort to align the interests of the company’s leadership with those of its shareholders, potentially strengthening stakeholder confidence and enhancing the company’s market positioning.
Judges Scientific plc announced that Tim Prestidge, Group Business Development Director, purchased 511 ordinary shares in the company, increasing his holding to 564 shares. This transaction, conducted on the AIM market of the London Stock Exchange, reflects internal confidence in the company’s strategy and potential for growth, potentially impacting stakeholder perceptions positively.
Judges Scientific plc has confirmed its full-year financial results for 2024, with no changes from the preliminary results published in March 2025. The company’s financial statements have been approved by the Board of Directors and audited, reinforcing its stable financial position and ongoing commitment to transparency. This announcement underscores Judges Scientific’s consistent performance and strategic focus on sustainable growth through acquisitions, which is likely to reassure stakeholders of its robust market positioning.
Judges Scientific plc reported a challenging trading year in 2024, with a 2% decrease in revenue and a 20% drop in adjusted operating profit, attributed to delays in a Geotek coring expedition and weaker order intake, particularly in China. Despite these challenges, the company completed three acquisitions and increased its cash conversion to normal levels. The year ended with a proposed final dividend increase of 10%, reflecting the company’s commitment to shareholder returns. Looking forward, Judges Scientific has commenced 2025 with a strong order book and expects performance to align with market expectations, bolstered by strategic acquisitions and a strengthened executive team.